Q-omics provides the consensus-scored SPATA31A3 profile across patient tissues and cancer cell-line models. SPATA31A3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SPATA31A3 is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, SPATA31A3 RNA expression shows 5,707 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, LUSC, and STAD as cancer lineages where SPATA31A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA31A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA31A3 survival associations across molecular data types. SPATA31A3 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA31A3 RNA expression–survival associations across cancer types. High SPATA31A3 expression shows unfavorable associations in LIHC, COAD, THCA, UCS and LUSC, but favorable associations in UVM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SPATA31A3 RNA expression.
This table summarizes SPATA31A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SPATA31A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA31A3 shows higher tumor expression in LUSC and PRAD. The LUSC box plot shows higher SPATA31A3 RNA expression in tumor versus normal tissue (log2 FC = +0.008, t-test p = .031).
This table shows molecular features associated with SPATA31A3 in patient tissues and cancer cell lines. In patient samples, SPATA31A3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA31A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
